Hopes that BeyondSpring will blossom on Nasdaq listing

9 March 2017

The level of investor interest in USA-based biopharma company BeyondSpring is about to become apparent with the company’s listing on the Nasdaq stock market.

BeyondSpring will trade under the stock symbol Nasdaq: BYSI following its initial public offering on Thursday, when the company’s chief executive Lan Huang rang the opening bell.

Potential investors will likely have been attracted by the progress of plinabulin, BeyondSpring’s lead asset, being developed to treat both non-small cell lung cancer (NSCLC) and a common and potentially life-threatening adverse effect of chemotherapy with docetaxel.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK